日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Informing the risk assessment related to lactation and drug exposure: A physiologically based pharmacokinetic lactation model for pregabalin

为哺乳期用药风险评估提供信息:基于生理学的普瑞巴林哺乳期药代动力学模型

Humerickhouse, Cameron; Pressly, Michelle; Lin, Zhoumeng; Guinn, Daphne; Samuels, Sherbet; Pfuma Fletcher, Elimika; Schmidt, Stephan

Safety and efficacy of navitoclax, a BCL-2 and BCL-X(L) inhibitor, in patients with relapsed or refractory lymphoid malignancies: results from a phase 2a study

navitoclax(一种 BCL-2 和 BCL-X(L) 抑制剂)在复发或难治性淋巴系统恶性肿瘤患者中的安全性和有效性:一项 2a 期研究的结果

de Vos, Sven; Leonard, John P; Friedberg, Jonathan W; Zain, Jasmine; Dunleavy, Kieron; Humerickhouse, Rod; Hayslip, John; Pesko, John; Wilson, Wyndham H

Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study

维奈托克联合低剂量阿糖胞苷治疗既往未接受治疗的急性髓系白血病患者:一项 Ib/II 期研究的结果

Wei, Andrew H; Strickland, Stephen A Jr; Hou, Jing-Zhou; Fiedler, Walter; Lin, Tara L; Walter, Roland B; Enjeti, Anoop; Tiong, Ing Soo; Savona, Michael; Lee, Sangmin; Chyla, Brenda; Popovic, Relja; Salem, Ahmed Hamed; Agarwal, Suresh; Xu, Tu; Fakouhi, Kaffa M; Humerickhouse, Rod; Hong, Wan-Jen; Hayslip, John; Roboz, Gail J

Utility of positron emission tomography-computed tomography in patients with chronic lymphocytic leukemia following B-cell receptor pathway inhibitor therapy

正电子发射断层扫描-计算机断层扫描在接受B细胞受体通路抑制剂治疗的慢性淋巴细胞白血病患者中的应用价值

Mato, Anthony R; Wierda, William G; Davids, Matthew S; Cheson, Bruce D; Coutre, Steven E; Choi, Michael; Furman, Richard R; Heffner, Leonard; Barr, Paul M; Eradat, Herbert; Ford, Sharanya M; Zhou, Lang; Verdugo, Maria; Humerickhouse, Rod A; Potluri, Jalaja; Byrd, John C

Venetoclax for patients with chronic lymphocytic leukemia who progressed during or after idelalisib therapy

Venetoclax 用于治疗在 idelalisib 治疗期间或之后病情进展的慢性淋巴细胞白血病患者。

Coutre, Steven; Choi, Michael; Furman, Richard R; Eradat, Herbert; Heffner, Leonard; Jones, Jeffrey A; Chyla, Brenda; Zhou, Lang; Agarwal, Suresh; Waskiewicz, Tina; Verdugo, Maria; Humerickhouse, Rod A; Potluri, Jalaja; Wierda, William G; Davids, Matthew S

Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

维奈托克治疗复发或难治性非霍奇金淋巴瘤患者的I期首次人体研究

Davids, Matthew S; Roberts, Andrew W; Seymour, John F; Pagel, John M; Kahl, Brad S; Wierda, William G; Puvvada, Soham; Kipps, Thomas J; Anderson, Mary Ann; Salem, Ahmed Hamed; Dunbar, Martin; Zhu, Ming; Peale, Franklin; Ross, Jeremy A; Gressick, Lori; Desai, Monali; Kim, Su Young; Verdugo, Maria; Humerickhouse, Rod A; Gordon, Gary B; Gerecitano, John F

Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia

使用维奈托克靶向BCL2治疗复发性慢性淋巴细胞白血病

Roberts, Andrew W; Davids, Matthew S; Pagel, John M; Kahl, Brad S; Puvvada, Soham D; Gerecitano, John F; Kipps, Thomas J; Anderson, Mary Ann; Brown, Jennifer R; Gressick, Lori; Wong, Shekman; Dunbar, Martin; Zhu, Ming; Desai, Monali B; Cerri, Elisa; Heitner Enschede, Sari; Humerickhouse, Rod A; Wierda, William G; Seymour, John F

Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia

维奈克拉单药治疗急性髓性白血病患者的 II 期临床研究的疗效和生物学相关性

Marina Konopleva, Daniel A Pollyea, Jalaja Potluri, Brenda Chyla, Leah Hogdal, Todd Busman, Evelyn McKeegan, Ahmed Hamed Salem, Ming Zhu, Justin L Ricker, William Blum, Courtney D DiNardo, Tapan Kadia, Martin Dunbar, Rachel Kirby, Nancy Falotico, Joel Leverson, Rod Humerickhouse, Mack Mabry, Richard

Phase 1 study of the safety, pharmacokinetics, and antitumour activity of the BCL2 inhibitor navitoclax in combination with rituximab in patients with relapsed or refractory CD20+ lymphoid malignancies

一项评估BCL2抑制剂navitoclax联合利妥昔单抗治疗复发或难治性CD20+淋巴瘤患者的安全性、药代动力学和抗肿瘤活性的I期研究

Roberts, Andrew W; Advani, Ranjana H; Kahl, Brad S; Persky, Daniel; Sweetenham, John W; Carney, Dennis A; Yang, Jianning; Busman, Todd B; Enschede, Sari H; Humerickhouse, Roderick A; Seymour, John F

Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease

慢性淋巴细胞白血病对 BCL2 抑制剂具有显著敏感性:navitoclax 治疗复发或难治性疾病患者的 I 期研究结果

Roberts, Andrew W; Seymour, John F; Brown, Jennifer R; Wierda, William G; Kipps, Thomas J; Khaw, Seong Lin; Carney, Dennis A; He, Simon Z; Huang, David C S; Xiong, Hao; Cui, Yue; Busman, Todd A; McKeegan, Evelyn M; Krivoshik, Andrew P; Enschede, Sari H; Humerickhouse, Rod